Jianchun Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jianchun Mao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Meng Li
State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Macau SAR, China
2 shared publicationsWei Hu
State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Macau SAR, China
2 shared publications- Yi Zhun Zhu
School of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization Macau University of Science and Technology Macau China
2 shared publications Jianghong Cai
State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Macau SAR, China
1 shared publicationJunyi Liao
State Key Laboratory of Quality Research in Chinese Medicine, School of Pharmacy Macau University of Science and Technology Macau China
1 shared publicationMenglin Zhu
State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Macau SAR, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 17 February 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-24
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease progression leads to joint deformity and associated loss of function, which significantly impacts the quality of life for sufferers and adds to losses in the labor force. In the past few decades, RA has attracted increased attention from researchers, the abnormal signaling pathways in RA are a very important research field in the diagnosis and treatment of RA, which provides important evidence for understanding this complex disease and developing novel RA-linked intervention targets. The current review intends to provide a comprehensive overview of RA, including a general introduction to the disease, historical events, epidemiology, risk factors, and pathological process, highlight the primary research progress of the disease and various signaling pathways and molecular mechanisms, including genetic factors, epigenetic factors, summarize the most recent developments in identifying novel signaling pathways in RA and new inhibitors for treating RA. therapeutic interventions including approved drugs, clinical drugs, pre-clinical drugs, and cutting-edge therapeutic technologies. These developments will hopefully drive progress in new strategically targeted therapies and hope to provide novel ideas for RA treatment options in the future.
- 17 February 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-24
Top Cited PapersOpen AccessSignaling pathways in rheumatoid arthritis: implications for targeted therapy
Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease progression leads to joint deformity and associated loss of function, which significantly impacts the quality of life for sufferers and adds to losses in the labor force. In the past few decades, RA has attracted increased attention from researchers, the abnormal signaling pathways in RA are a very important research field in the diagnosis and treatment of RA, which provides important evidence for understanding this complex disease and developing novel RA-linked intervention targets. The current review intends to provide a comprehensive overview of RA, including a general introduction to the disease, historical events, epidemiology, risk factors, and pathological process, highlight the primary research progress of the disease and various signaling pathways and molecular mechanisms, including genetic factors, epigenetic factors, summarize the most recent developments in identifying novel signaling pathways in RA and new inhibitors for treating RA. therapeutic interventions including approved drugs, clinical drugs, pre-clinical drugs, and cutting-edge therapeutic technologies. These developments will hopefully drive progress in new strategically targeted therapies and hope to provide novel ideas for RA treatment options in the future.
- Open Access
- 1 April 2021
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (4) , e376
NAV2 positively modulates inflammatory response of fibroblast‐like synoviocytes through activating Wnt/β‐catenin signaling pathway in rheumatoid arthritis
- 1 April 2021
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (4) , e376
Open AccessNAV2 positively modulates inflammatory response of fibroblast‐like synoviocytes through activating Wnt/β‐catenin signaling pathway in rheumatoid arthritis